Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ventyx Biosciences ( (VTYX) ) has issued an update.
On January 7, 2026, Ventyx Biosciences, Inc. entered into a Merger Agreement with Eli Lilly and Company and RYLS Merger Corporation under which RYLS Merger Corporation will merge with and into Ventyx, and Ventyx will survive as a wholly owned subsidiary of Eli Lilly. The transaction marks a significant shift in Ventyx’s corporate structure and ownership, integrating the company into a major global pharmaceutical group and potentially reshaping its strategic direction.
On March 3, 2026, Ventyx held a virtual special meeting of stockholders at which holders of 45,810,746 common shares were present in person or by proxy out of 71,760,778 shares outstanding as of the January 21, 2026 record date. Stockholders approved the Merger Agreement and, on an advisory basis, the merger-related executive compensation, while a contingent proposal to adjourn the meeting became moot, clearing the way for completion of the merger and associated leadership compensation arrangements.
The most recent analyst rating on (VTYX) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Ventyx Biosciences stock, see the VTYX Stock Forecast page.
Spark’s Take on VTYX Stock
According to Spark, TipRanks’ AI Analyst, VTYX is a Neutral.
The score is held back primarily by weak fundamentals typical of a development-stage biotech (no revenue, ongoing losses, and negative free cash flow), despite a low-debt balance sheet. Offsetting this, technicals show strong positive momentum with price well above key moving averages, and corporate events are supportive due to the announced all-cash acquisition by Eli Lilly, which reduces standalone business risk and increases visibility on value realization. Valuation remains constrained by losses (negative P/E) and no dividend support.
To see Spark’s full report on VTYX stock, click here.
More about Ventyx Biosciences
Ventyx Biosciences, Inc. is a biopharmaceutical company operating in the life sciences sector. The company focuses on developing innovative therapies and drug candidates, positioning itself within the broader pharmaceutical and biotechnology industry as a research-driven organization pursuing strategic transactions with larger pharmaceutical partners.
Average Trading Volume: 3,631,985
Technical Sentiment Signal: Buy
Current Market Cap: $1B
Learn more about VTYX stock on TipRanks’ Stock Analysis page.